Chimeric antigen receptor transduced T cells: Tuning up for the next generation. Issue 9 (27th November 2017)

• Record Type: Journal Article
• Authors: Schubert, Maria‐Luisa; Hoffmann, Jean‐Marc; Dreger, Peter; Müller‐Tidow, Carsten; Schmitt, Michael
• Is Part Of: International journal of cancer. Volume 142:Issue 9(2018)
• Page Start: 1738
• Page End: 1747
• Publication Date: 2017-11-27
• Subjects: chimeric antigen receptor (CAR) -- CAR T cells -- CAR T cell design -- immunotherapy -- hematologic malignancies -- clinical CAR trials -- solid tumors; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.31147
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract : Chimeric antigen receptor (CAR) T cell therapy has recently achieved impressive clinical outcome in patients with CD19‐positive hematologic malignancies. Extrapolation of CAR T cell treatment to solid tumors, however, has not yet yielded similar results. This might be due to intrinsic causes, e.g. insufficient CAR T cell activation or CAR toxicity as well as extrinsic factors displaying an unfavorable tumor environment for CAR T cells by raising physical and chemical barriers. In this review, we discuss the advantages as well as major obstacles of CAR T cell therapy, particularly in the context of solid tumors, and focus on efforts and novel strategies in CAR T cell development.